UBS downgrades Nykaa stock rating to Neutral on slower beauty margin growth

UBS downgraded FSN Ecommerce Ventures (Nykaa) from Buy to Neutral, maintaining its INR260.00 price target, due to slower-than-expected margin improvement in the beauty and personal care segment. The investment bank subsequently reduced its medium-term EBITDA estimates for Nykaa by 3-6%. Based on these revised projections, UBS now considers Nykaa's current trading multiples of 61x and 41x FY27e and FY28e EV/EBITDA, respectively, to represent fair valuation.

Analysis

UBS has downgraded FSN Ecommerce Ventures (Nykaa) from Buy to Neutral, while maintaining its price target of INR260.00, signaling a reassessment of the company's near-term growth versus its valuation. The core driver for this downgrade is the slower-than-expected margin improvement within the critical Beauty and Personal Care (BPC) segment. Despite projecting robust top-line growth for Q2FY26, with BPC GMV and revenue expected to increase by 26% year-over-year, UBS anticipates only a 50 basis point improvement in the segment's EBITDA margin. This profitability lag has prompted the bank to reduce its medium-term EBITDA estimates for Nykaa by 3-6%. Consequently, UBS now views the stock's valuation, which trades at high forward multiples of 61x FY27e and 41x FY28e EV/EBITDA, as fair rather than attractive. The fashion segment's outlook is slightly more positive on the cost front, with an expected decline in cash burn, though its revenue growth of 11% is projected to be less than half that of the BPC segment.

Key Decisions for Investors

• Investors should moderate expectations for near-term capital appreciation, as the UBS downgrade to Neutral suggests the stock is now considered fairly valued, removing the previous catalyst for a 'Buy' rating.
• The primary metric to monitor is the EBITDA margin in the Beauty and Personal Care segment; any further deceleration in its improvement could pose a significant risk to future earnings forecasts and valuation.
• Given that strong top-line growth is already priced in, the high forward multiples of 61x and 41x EV/EBITDA leave little room for error in execution on profitability, making the stock sensitive to any negative earnings revisions.